ARVEE

Arvee Laboratories (India) Share Price

₹183.34 -4.97 (-2.64%)

28 Dec, 2024 01:57

SIP TrendupStart SIP in ARVEE

Start SIP

Performance

  • Low
  • ₹181
  • High
  • ₹195
  • 52 Week Low
  • ₹117
  • 52 Week High
  • ₹315
  • Open Price₹195
  • Previous Close₹188
  • Volume2,944

Investment Returns

  • Over 1 Month + 18.03%
  • Over 3 Month + 3.29%
  • Over 6 Month -1.69%
  • Over 1 Year + 0.32%
SIP Lightning

Smart Investing Starts Here Start SIP with Arvee Laboratories (India) for Steady Growth!

Invest Now

Arvee Laboratories (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 88.7
  • PEG Ratio
  • 2.2
  • Market Cap Cr
  • 202
  • P/B Ratio
  • 6.9
  • Average True Range
  • 11.84
  • EPS
  • 2.07
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.81
  • RSI
  • 51.2
  • MFI
  • 62.42

Arvee Laboratories (India) Financials

Arvee Laboratories (India) Technicals

EMA & SMA

Current Price
₹183.34
-4.97 (-2.64%)
pointer
  • stock-down_img
  • Bullish Moving Average 10
  • stock-up_img
  • Bearish Moving Average 6
  • 20 Day
  • ₹182.94
  • 50 Day
  • ₹179.07
  • 100 Day
  • ₹178.99
  • 200 Day
  • ₹175.04

Resistance and Support

186.29 Pivot Speed
  • R3 206.51
  • R2 200.75
  • R1 192.05
  • S1 177.59
  • S2 171.83
  • S3 163.13

What's your outlook on Arvee Laboratories (India)?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Arvee Laboratories (India) has an operating revenue of Rs. 36.97 Cr. on a trailing 12-month basis. An annual revenue de-growth of -51% needs improvement, Pre-tax margin of 6% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 6% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 79 which is a FAIR score but needs to improve its earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 83 indicates it belongs to a poor industry group of Chemicals-Specialty and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Arvee Laboratories (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results & Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2024-08-13 Quarterly Results
2024-02-13 Quarterly Results (Revised) issue in the ratio of 1:1 of Rs. 10/-.
2023-11-07 Quarterly Results
2023-08-11 Quarterly Results

Arvee Laboratories (India) F&O

Arvee Laboratories (India) Shareholding Pattern

73.5%
26.34%
0.16%

About Arvee Laboratories (India)

  • NSE Symbol
  • ARVEE
  • BSE Symbol
  • Managing Director
  • Mr. Shalin Sudhakarbhai Patel
  • ISIN
  • INE006Z01016

Similar Stocks to Arvee Laboratories (India)

Arvee Laboratories (India) FAQs

Arvee Laboratories (India) share price is ₹183 As on 28 December, 2024 | 01:43

The Market Cap of Arvee Laboratories (India) is ₹202 Cr As on 28 December, 2024 | 01:43

The P/E ratio of Arvee Laboratories (India) is 88.7 As on 28 December, 2024 | 01:43

The PB ratio of Arvee Laboratories (India) is 6.9 As on 28 December, 2024 | 01:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23